International Trade Bulletin - Volume 1, Issue 17
Client Alert | 1 min read | 12.15.06
Inside this issue:
- TRENDS IN TRADE REMEDIES IN THE SPOTLIGHT
- EUROPE IN THE SPOTLIGHT
- MARKET ACCESS: After Doha: Practical Approaches for Cutting the Costs of Trade - Making the Most of FTAs
- COUNTERVAILING: Commerce Initiates First Countervailing Duty Investigation Involving Chinese Subsidies in 15 Years
- SANCTIONS: Change expected soon in scope of US sanctions on North Korea
- SANCTIONS: Recent Changes in U.S. Policy Expand Business Opportunities in Sudan
- U.S. LEGISLATION: Hours before the close of the 109th Session of Congress, the House and Senate approved a package of trade legislation with wide-ranging implications for the international business community
- AVIATION: U.S. DOT Decision to Scuttle Foreign Control Rule Leaves U.S.-EU Open Skies Accord in Doubt
- REGULATORY: REACH Regulation on track for adoption by EU Council
Contacts
Insights
Client Alert | 9 min read | 10.21.26
The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .
Client Alert | 2 min read | 10.21.26
Client Alert | 3 min read | 10.21.26
Private Investigations Act Series: Temporal, material and territorial scope
Client Alert | 7 min read | 10.21.26
